Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT

被引：0

作者：

Ward, John ^{[1
]}

Noy, Ariela ^{[2
]}

Ulaner, Gary ^{[3
]}

Riedl, Christopher ^{[3
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Southampton, Hants, England

[2] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Nucl Med, 1275 York Ave, New York, NY 10065 USA

来源：

CLINICAL NUCLEAR MEDICINE | 2018年 / 43卷 / 05期

关键词：

F-18-FDG PET; CT; adalimumab; Epstein Barr virus-related lymphoproliferative disorder;

D O I：

10.1097/RLU.0000000000002054

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis. We present a 51-year-old woman with psoriatic arthritis on methotrexate and infliximab for 12 years. Adalimumab replaced infliximab because of worsening symptoms. Following 3 doses administered 1 week apart, rapidly enlarging cervical lymph nodes developed. Biopsy revealed Epstein-Barr virus-related polymorphic lymphoproliferative disorder. F-18-FDG PET/CT demonstrated widespread hypermetabolic lymphadenopathy; follow-up at 5 weeks off adalimumab revealed almost complete resolution of this adenopathy. This is most consistent with Epstein-Barr virus-related lymphoproliferative disorder secondary to tumor necrosis factor inhibition.

引用

页码：344 / 345

页数：2

共 50 条

[41] Epstein-Barr Virus-Related Lymphoproliferative Disorders-Associated Polymyositis in a Patient With Rheumatoid Arthritis
Kaieda, Shinjiro
Koga, Takuma
Yamada, Kyohei
Ida, Hiroaki
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 (8S) : S781 - S782
[42] Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma
Pfeffermann, Lisa-Marie
Pfirrmann, Verena
Huenecke, Sabine
Bremm, Melanie
Bonig, Halvard
Kvasnicka, Hans-Michael
Klingebiel, Thomas
Bader, Peter
Rettinger, Eva
CYTOTHERAPY, 2018, 20 (06) : 839 - 850
[43] FDG-PET/CT findings of chronic active Epstein-Barr virus infection
Toriihara, Akira
Arai, Ayako
Nakadate, Masashi
Yamamoto, Kouhei
Imadome, Ken-Ichi
Miura, Osamu
Tateishi, Ukihide
LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1470 - 1473
[44] EPSTEIN-BARR VIRUS AND LYMPHOPROLIFERATIVE DISORDERS
SULLIVAN, JL
SEMINARS IN HEMATOLOGY, 1988, 25 (03) : 269 - 279
[45] Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
Liu, Li
Liu, Qifa
Feng, Sizhou
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
[46] Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder in a Renal Transplant Recipient Treated with Tacrolimus and Antithymocyte Globulin
Agnes L. F. Chan
Hue-Yu Wang
Clinical Drug Investigation, 2003, 23 : 281 - 283
[47] Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder
Birkeland, SA
Bendtzen, K
TRANSPLANTATION, 1996, 61 (09) : 1425 - 1426
[48] Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a renal transplant recipient treated with tacrolimus and antithymocyte globulin
Chan, ALF
Wang, HY
CLINICAL DRUG INVESTIGATION, 2003, 23 (04) : 281 - 283
[49] Spectrum of Epstein-Barr virus-related diseases: a pictorial review
Maeda, Eriko
Akahane, Masaaki
Kiryu, Shigeru
Kato, Nobuyuki
Yoshikawa, Takeharu
Hayashi, Naoto
Aoki, Shigeki
Minami, Manabu
Uozaki, Hiroshi
Fukayama, Masashi
Ohtomo, Kuni
JAPANESE JOURNAL OF RADIOLOGY, 2009, 27 (01) : 4 - 19
[50] The Importance Of Epigenetic Alterations In Epstein-Barr Virus-Related Lymphomas
Takacs, Maria
Segesdi, Judit
Banati, Ferenc
Koroknai, Anita
Wolf, Hans
Niller, Hans Helmut
Minarovits, Janos
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2009, 1 (02):

← 1 2 3 4 5 →